165 related articles for article (PubMed ID: 6572558)
1. Evidence of a treatment dose response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin's lymphoma.
Greene MH; Young RC; Merrill JM; DeVita VT
Cancer Res; 1983 Apr; 43(4):1891-8. PubMed ID: 6572558
[TBL] [Abstract][Full Text] [Related]
2. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
[TBL] [Abstract][Full Text] [Related]
3. Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer: a study of five randomized clinical trials.
Greene MH; Boice JD; Greer BE; Blessing JA; Dembo AJ
N Engl J Med; 1982 Dec; 307(23):1416-21. PubMed ID: 6752720
[TBL] [Abstract][Full Text] [Related]
4. Quantitative risk of second cancer in patients in first complete remission from early stages of Hodgkin's disease.
Henry-Amar M
NCI Monogr; 1988; (6):65-72. PubMed ID: 3352791
[TBL] [Abstract][Full Text] [Related]
5. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
6. Second malignant neoplasms following childhood Hodgkin's disease: treatment and splenectomy as risk factors.
Meadows AT; Obringer AC; Marrero O; Oberlin O; Robison L; Fossati-Bellani F; Green D; Voûte PA; Morris-Jones P; Greenberg M
Med Pediatr Oncol; 1989; 17(6):477-84. PubMed ID: 2586362
[TBL] [Abstract][Full Text] [Related]
7. Second cancers after radiotherapy and chemotherapy for early stages of Hodgkin's disease.
Henry-Amar M
J Natl Cancer Inst; 1983 Nov; 71(5):911-6. PubMed ID: 6580491
[TBL] [Abstract][Full Text] [Related]
8. Association of thyroid carcinoma with malignant lymphoma.
Bakri KM; Shimaoka K; Gajera R; Getaz EP; Friedman M; Walsh D; Tsukada Y
Jpn J Clin Oncol; 1983 Dec; 13(4):645-55. PubMed ID: 6645082
[TBL] [Abstract][Full Text] [Related]
9. Risk of leukemia following treatment for non-Hodgkin's lymphoma.
Travis LB; Curtis RE; Stovall M; Holowaty EJ; van Leeuwen FE; Glimelius B; Lynch CF; Hagenbeek A; Li CY; Banks PM
J Natl Cancer Inst; 1994 Oct; 86(19):1450-7. PubMed ID: 8089863
[TBL] [Abstract][Full Text] [Related]
10. Incidence of second solid cancer in patients after treatment of Hodgkin's disease.
Glanzmann C; Veraguth A; Lütolf UM
Strahlenther Onkol; 1994 Mar; 170(3):140-6. PubMed ID: 8160093
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
12. Risk of leukemia after chemotherapy and radiation treatment for breast cancer.
Curtis RE; Boice JD; Stovall M; Bernstein L; Greenberg RS; Flannery JT; Schwartz AG; Weyer P; Moloney WC; Hoover RN
N Engl J Med; 1992 Jun; 326(26):1745-51. PubMed ID: 1594016
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
[TBL] [Abstract][Full Text] [Related]
14. Risk of second cancers after treatment for Hodgkin's disease.
Tucker MA; Coleman CN; Cox RS; Varghese A; Rosenberg SA
N Engl J Med; 1988 Jan; 318(2):76-81. PubMed ID: 3336397
[TBL] [Abstract][Full Text] [Related]
15. Incidence of acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease.
Pedersen-Bjergaard J; Larsen SO
N Engl J Med; 1982 Oct; 307(16):965-71. PubMed ID: 7110299
[TBL] [Abstract][Full Text] [Related]
16. Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study.
Sacchi S; Marcheselli L; Bari A; Marcheselli R; Pozzi S; Luminari S; Lombardo M; Buda G; Lazzaro A; Gobbi PG; Stelitano C; Morabito F; Quarta G; Brugiatelli M
Haematologica; 2008 Mar; 93(3):398-404. PubMed ID: 18268277
[TBL] [Abstract][Full Text] [Related]
17. Consolidative involved field radiotherapy after high dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma: a case-control study.
Oehler-Jänne C; Taverna C; Stanek N; Negretti L; Lütolf UM; Ciernik IF
Hematol Oncol; 2008 Jun; 26(2):82-90. PubMed ID: 18085574
[TBL] [Abstract][Full Text] [Related]
18. Secondary lung tumors in hematological patients.
Amadori D; Ronconi S
Semin Respir Crit Care Med; 2005 Oct; 26(5):520-6. PubMed ID: 16267703
[TBL] [Abstract][Full Text] [Related]
19. Leukemia following low-dose total body irradiation and chemotherapy for non-Hodgkin's lymphoma.
Travis LB; Weeks J; Curtis RE; Chaffey JT; Stovall M; Banks PM; Boice JD
J Clin Oncol; 1996 Feb; 14(2):565-71. PubMed ID: 8636772
[TBL] [Abstract][Full Text] [Related]
20. Leukemia as a second malignancy.
Uppin MS; Paul TR; Rajappa S; Gayathri K; Jacob R; Uppin SG
Indian J Pathol Microbiol; 2007 Jul; 50(3):644-7. PubMed ID: 17883171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
